ClinConnect ClinConnect Logo
Search / Trial NCT05292235

Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 15, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at the results and potential complications of different surgical treatments for a condition called Benign Prostatic Hyperplasia (BPH), which is a common issue that affects older men and can cause problems with urination. Researchers are collecting information from patients in various hospitals in Hong Kong to understand how well these treatments work and how safe they are.

To participate in this study, you need to be a man who is at least 18 years old. Unfortunately, if someone is unable to give their consent to participate, they cannot join the trial. If you choose to take part, you can expect to help contribute valuable information that may improve future treatments for men with BPH. The trial is currently recruiting participants, so it’s a great opportunity to be involved in research that could benefit many others facing similar health issues.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Patient at the age of 18 or above
  • Exclusion Criteria:
  • Patient is unable to give consent

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Shatin, , Hong Kong

Hong Kong, , Hong Kong

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Trial Officials

Chi Fai NG, MD

Principal Investigator

Chinese University of Hong Kong

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials